Home / Market News / $TNDM

$TNDM news and market catalysts

The 14 most recent market catalysts affecting $TNDM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

14 catalysts 1 high impact 8 bullish 3 bearish Medical Devices
Nov 18, 2026 Corporate Catalyst Bullish Impact 65
Stifel Upgrades Tandem Diabetes Care to Buy
Stifel, a prominent financial services firm, has upgraded its rating on Tandem Diabetes Care (TNDM) from its previous stance to a 'Buy' and established a price target of $26. This …
Nov 18, 2026 Corporate Catalyst Bullish Impact 65
Stifel Upgrades Tandem Diabetes Care to Buy, Price Target is $26
Stifel has upgraded its rating for Tandem Diabetes Care (TNDM) from its previous stance to 'Buy' and established a new price target of $26. This analyst upgrade signals a more opti…
Nov 13, 2026 Corporate Catalyst Bullish Impact 75
Tandem Diabetes Care Receives FDA Clearance for Tubeless Tandem Mobi System
Tandem Diabetes Care (TNDM) announced FDA clearance for its Tandem Mobi system as a tubeless automated insulin delivery (AID) system, allowing for extended wear. This is a signific…
Nov 12, 2026 Corporate Catalyst Bullish Impact 65
Tandem Diabetes Care Receives Health Canada Approval for t:slim X2 Insulin Pump with Abbott FreeStyle Libre 3 Plus Compatibility
Tandem Diabetes Care secured Health Canada approval for its t:slim X2 insulin pump, allowing compatibility with Abbott's FreeStyle Libre 3 Plus sensor. This is significant because …
Nov 12, 2026 Corporate Catalyst Bullish Impact 65
Tandem Diabetes Care Receives Health Canada Approval for t:slim X2 Insulin Pump License Amendment
Tandem Diabetes Care announced Health Canada approval for an amendment to its t:slim X2 insulin pump license. This approval is significant because it adds compatibility with Abbott…
Nov 5, 2026 Corporate Catalyst Neutral Impact 75
Tandem Diabetes Care Appoints Jeannette Bankes as President and CEO
Tandem Diabetes Care (TNDM) has appointed Jeannette Bankes as its new President and CEO, replacing long-serving CEO John Sheridan who retired. This is a significant leadership chan…
Nov 5, 2026 Corporate Catalyst Bullish Impact 75
Tandem Diabetes Care Reports Third Quarter 2026 Financial Results
Tandem Diabetes Care reported solid third-quarter 2026 financial results, with worldwide sales of $283.7 million and a significant 270 basis point increase in gross margin year-ove…
Oct 7, 2026 Corporate Catalyst Neutral Impact 55
Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18
Barclays analyst Christopher Pasquale has initiated coverage on Tandem Diabetes Care (TNDM) with an 'Equal-Weight' rating and a price target of $18. This event is significant as ne…
Sep 30, 2026 Corporate Catalyst Bearish Impact 55
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20
Citigroup analyst Joanne Wuensch maintained a 'Neutral' rating on Tandem Diabetes Care (TNDM) but significantly lowered the price target from $24 to $20. This action indicates a mo…
Sep 28, 2026 Corporate Catalyst Bullish Impact 75
Tandem Expands Mobi Availability To 12 International Markets, Pairing Control-IQ+ Predictive Algorithm, Studied In Type 1, Pregnancy And Type 2 Diabetes, With Dexcom G7 Sensor
This headline signals a significant growth catalyst for Tandem Diabetes Care (TNDM) as it expands its advanced Mobi system into 12 new international markets. The integration of the…
Aug 21, 2026 Corporate Catalyst Neutral Impact 55
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating
William Blair's initiation of coverage on Tandem Diabetes Care with an Outperform rating signals a positive outlook from a reputable financial institution. This event is significan…
Aug 7, 2026 Corporate Catalyst Bearish Impact 55
RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26
RBC Capital's analyst Kendall Au maintained an 'Outperform' rating for Tandem Diabetes Care (TNDM), signaling continued confidence in the company's long-term prospects. However, th…
Aug 7, 2026 Corporate Catalyst Bullish Impact 85
Tandem Diabetes Care shares are trading higher after the company reported better-than-expected Q2 EPS results and reaffirmed its FY2026 sales guidance.
This headline represents a significant corporate catalyst for Tandem Diabetes Care (TNDM). Exceeding EPS expectations and, crucially, reaffirming ambitious long-term sales guidance…
Jul 15, 2026 Corporate Catalyst Bearish Impact 55
Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20
Mizuho analyst Anthony Petrone maintained a Neutral rating on Tandem Diabetes Care (TNDM) but lowered the price target from $24 to $20. This action signals a slightly less optimist…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.